Navigation Links
EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
Date:9/9/2013

WESTBURY, N.Y., Sept. 9, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that its EECP Therapy has been given a lla Class of Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC's annual meeting which took place from August 31 to September 3, 2013 in Amsterdam, the Netherlands. 

The IIa classification signifies that the weight of evidence and level of opinion are in favor of a treatment and, in this case, that physicians should consider EECP Therapy as a treatment option for patients suffering from refractory angina.

Last November, The American College of Cardiology Foundation and The American Heart Association (ACCF/AHA) Task Force on Practice Guidelines issued its new Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. In this Guideline, EECP Therapy retained the same IIb Class of Recommendation rating it had received in the ACC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina.  The Company has been in active communication with the ACCF/AHA task force, as well as its guideline writing committee, requesting a review of more recent data than was referenced in the 2012 Guideline, for the purpose of upgrading EECP Therapy's level of recommendation to lla in its future guideline.

"It is a breakthrough that EECP Therapy was included in the ESC Guidelines for the first time, and at the same time was given a level IIa recommendation, which means it 'should be considered' as a treatment option as opposed to 'may be considered' recommendation for a IIb rating," said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "We are pleased that the European Society of Cardiology has recognized the value and efficacy of this treatment, as has been demonstrated by many studies. On behalf of all heart patients, we thank the many physicians in the U.S. and Europe who have done great research on EECP Therapy and presented data to ESC for consideration."

"Throughout the past decade, EECP Therapy has been offered to hundreds of thousands of patients in numerous centers and hospitals in the Unites States and abroad. During this time, we have gathered a wealth of data from many different studies, including randomized controlled trials published in peer-reviewed journals, and have received countless testimonials regarding an improvement to patients' quality of life," continued Dr. Ma. "We believe this treatment option should be made available to a wider patient base. Our responsibility is not only to support and improve this technology, but also to champion the patient who is not receiving this therapy and its benefits. Furthermore, we have a social obligation to support healthcare cost reduction through expanding role of EECP Therapy, which has been demonstrated in clinical literature to reduce re-hospitalizations and emergency room visits. We believe this high recommendation by ESC should help promote a broader acceptance of the EECP Therapy around the world."

About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products.  The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain markets. Additional information is available on the Company's website at www.vasomedical.com

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com  

Media Contact:
Samantha Wolf
KCSA Strategic Communications
212-896-1220
swolf@kcsa.com


'/>"/>
SOURCE Vasomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Achieve Beyond Pediatric Therapy Offers Exciting CEU Workshop in Virginia
2. XBiotech Announces it is Developing Therapy for MRSA
3. KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
4. SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
5. seca Supports Obesity Therapy with the New medical Body Composition Analyzer
6. Cancer Experts Detail New Approaches to Liver Cancer Treatment with Stereotactic Ablative Radiotherapy
7. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
8. AnaptysBio Expands Immunotherapy Portfolio With Anti-PD-1 Antibody Combinations
9. HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
10. Cancer Research Institute Celebrating 60th Anniversary, Honoring Immunotherapy Leaders
11. Elektas Leksell Gamma Knife Perfexion and Elekta Infinity Place First and Second in 2013 KLAS Radiation Therapy Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
(Date:5/25/2016)... , May 25, 2016 MedDay, a ... announces that an oral presentation entitled "High doses of biotin ... trial" will be given by Professor Ayman Tourbah , ... Congress of the European Academy of Neurology (EAN) in ... related disorders 3" will take place on Sunday, 29 May ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... May 2016 – Lips ... central to popular cosmetic improvement efforts. Record numbers of clients now ask about lip ... or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , The ...
(Date:5/26/2016)... (PRWEB) , ... May 26, ... ... organization promoting quality-based imaging practices, is seeking nominations to serve on its ... diagnostic imaging. , “RadSite’s quality-benchmarking activities incorporate key process and ...
(Date:5/26/2016)... ... May 26, 2016 , ... In Madeira Beach Florida, a ... a single drawbridge, citizens formed an organization, Madeira Beach United, to oppose two development ... the small town center to a high rise urban environment. , According to the ...
(Date:5/26/2016)... ... 26, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... High blood pressure affects millions of people worldwide, and many patients use prescription ... heart disease, stroke, kidney disease, and hardening of the arteries. However, prescription medications ...
(Date:5/26/2016)... ... May 26, 2016 , ... With long-term experience ... President of Business Intelligence and Informatics, effective immediately. http://www.fluidedgeconsulting.com , As ... as a healthcare business and financial strategist for over 20 years. By ...
Breaking Medicine News(10 mins):